S&CO Inc. Lowers Position in Insulet Corporation $PODD

S&CO Inc. lessened its stake in shares of Insulet Corporation (NASDAQ:PODD) by 47.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,385 shares of the medical instruments supplier’s stock after selling 5,770 shares during the period. S&CO Inc.’s holdings in Insulet were worth $2,006,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PODD. Illinois Municipal Retirement Fund lifted its position in shares of Insulet by 41.3% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock valued at $3,780,000 after buying an additional 3,514 shares in the last quarter. ProShare Advisors LLC raised its stake in Insulet by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 15,657 shares of the medical instruments supplier’s stock worth $4,919,000 after acquiring an additional 1,055 shares during the period. Profund Advisors LLC raised its stake in Insulet by 9.7% during the 2nd quarter. Profund Advisors LLC now owns 1,101 shares of the medical instruments supplier’s stock worth $346,000 after acquiring an additional 97 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Insulet during the second quarter valued at approximately $1,081,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Insulet in the second quarter worth approximately $7,002,000.

Insider Buying and Selling

In other news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.39% of the company’s stock.

Insulet Stock Down 1.1%

PODD opened at $319.82 on Monday. The company has a market capitalization of $22.51 billion, a PE ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The firm has a 50-day simple moving average of $325.06 and a two-hundred day simple moving average of $310.30. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the previous year, the firm posted $1.08 earnings per share. The business’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Jefferies Financial Group raised their price target on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a report on Thursday. Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, UBS Group upped their price objective on Insulet from $320.00 to $355.00 and gave the stock a “neutral” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $371.38.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.